PCVX Stock — Vaxcyte Inc.

Vaxcyte Inc. (PCVX)

Updated October 16, 2026.

PCVX is a Stock. Total return is 143.3% over the past 6.3 years, 31.0 points behind SPY at 174.3%.

Vaxcyte is a clinical-stage vaccine company developing conjugate and protein vaccines to prevent bacterial infectious diseases, with its lead candidate VAX-24 targeting pneumococcal disease in infants and other candidates in development for adult pneumococcal disease, Group A Streptococcus, periodontitis, and shigellosis. As an early-stage biopharmaceutical company, it does not currently distribute income to shareholders. The company appeals to investors with high risk tolerance seeking exposure to vaccine innovation and infectious disease prevention.

PCVX performance versus SPY

Price and return data through 2026-10-16.

Total return is 143.3% over the past 6.3 years, 31.0 points behind SPY at 174.3%. Over the past year its total return — price change plus distributions reinvested — is 46.0%. Its deepest 1-year drawdown was 28.0%.

PCVX key facts

Asset type

Stock

Asset class

Equity

Inception date

06/12/2020

Distribution frequency

None

Last close

$63.62 (as of 2026-10-16)

Market cap

$9,938,575,036

Average volume

3249905.0

Beta

1.234

Payout ratio

0.0%

EPS

$-7.62

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PCVX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 28.0%.

Who may consider PCVX — and who may not

It is a weaker fit for investors who need monthly cash flow (PCVX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PCVX

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions